In the Coming Year We Should Abandon Interferons and Glatiramer Acetate as First Line Therapy for MS: Commentary

Multiple Sclerosis - United States
doi 10.1177/1352458512470507
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

SAGE Publications

Related search

Beta Interferons and Glatiramer Acetate for Treatment of MS: TA Guidance 2018

Progress in Neurology and Psychiatry
PsychiatryMental HealthNeurologyPsychiatric Mental Health
2018English

Should We Abandon the Monroe Doctrine?

The Journal of Race Development
1914English

Editorial: Should We Abandon HCV Genotype Testing? Maybe

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Should We Definitively Abandon Prophylaxis for Patent Ductus Arteriosus in Preterm New-Borns?

Clinics
Medicine
2011English

CD8+ T Cells Are Required for Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease

PLoS ONE
Multidisciplinary
2013English

Imaginary Worlds and Efficiency Frontiers: Should We Abandon the IQWiG Health Technology Assessment Model?

INNOVATIONS in pharmacy
2017English

Should FPGAS Abandon the Pass-Gate?

2013English

NSAIDs Questionable as First-Line Therapy for Rheumatic Conditions in the Elderly

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1994English

Designer Babies: Where Should We Draw the Line?

Journal of Medical Ethics
ArtsHumanitiesLegal AspectsHealth PolicyHealthEthicsIssues
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy